Sepsis a whole-body inflammatory response to an infection and the worldwide incidence of the disease is estimated to be 18 million cases per year.
Opsonix, Wyss Institute's newest startup, has announced that it will use the $8 million in proceeds from Baxter Ventures and private investor Hansjorg Wyss to develop an advanced therapy for sepsis.
The treatment is especially designed to remove infectious pathogens and toxins from circulating blood. It offers a new broad-spectrum approach to treat blood-borne infectious diseases, including sepsis.
When the FcMBL is attached to the membrane of a dialyzer-type device, it can remove a broad range of bacteria, fungi, parasites, viruses, and toxins responsible for initiating the sepsis cascade. Opsonix's therapy has been designed to work in synergy with conventional antibiotic treatments.
"Opsonix's pathogen-extracting therapy provides a novel therapeutic solution leveraging the broad binding activities of a natural human protein that may rapidly remove sepsis-causing pathogens - and the toxins they release - from a patient's blood. With our FcMBL-based pathogen-extracting therapy, treatment of blood-borne infectious disease can be initiated earlier in the course of infection, when it is most needed, without having to wait to identify the disease-causing pathogen. With the strong support of our investors and a compelling body of evidence developed by our scientific founders, Opsonix will move forward expeditiously with preclinical studies to advance our pathogen-extracting therapy," said Eric Devroe, Ph.D., Founder and Chief Executive Officer of Opsonix.